Lamprou Lab

Our state-of-the-art research Lab is emerging new materials and manufacturing techniques, in order to address the challenges associated with the manufacture of pharmaceutical systems that will teach new tricks to old drugs and on the development of new personalised medical devices and implants. In order to achieve this goal, we are using emerging technologies such as Additive Manufacturing (3D Printing, 4D Printing and Bioprinting), Electrohydrodynamic Processes (Electrospinning & Electrospraying), Microfluidics (including lab-on-a-chip / organ-on-a-chip), and BioMEMS. With several laboratories, which are fitted with modern equipment, our Research Lab offers an excellent environment for research. Our current work builds a bridge between engineering, pharmaceutical and medical research. Our research focuses on four major areas using Emerging Technologies: nanoparticles for imaging & therapeutic applications, lab-on-a-chip & microfluidic devices, implants for therapeutic delivery & tissue engineering, and sustainability in the manufacturing of pharmaceuticals. Our studies include: conceptualization, formulation / manufacturing, advanced physicochemical characterization, computational modelling (e.g., Finite Element Analysis (FEA), Computational Fluid Dynamics (CFD)), and in vitro, ex vivo & in vivo evaluation. Our Lab has been recognized as world leaders in 3D Printing & Microfluidics. PubMed-based algorithms placed us in the top 0.01% of scholars in the world writing about Printing, in the top 0.07% of scholars in the world writing about Microfluidics, and in the top 0.6% of scholars in the world writing about nanofibers, over the past 10 years. The lab has achieved a high level of sustainability by successfully implementing the recommendations in the Laboratory Efficiency Assessment Framework (LEAF) pilot program and has been recognized for its efforts with a Gold Award.